The vaccine peptide rindopepimut was synthesized according to the small amino acid sequence around the fusion site on EGFRvIII.180 This vaccine peptide has shown excellent safety and efficacy in both the phase I and phase II clinical trials.104,181 However, the difference between patients receiving the rindopepimut vaccine and those receiving the placebo vaccine could not be reproduced in phase III clinical trial.105 The possible reason is that rindopepimut selected out GBM cells with unmutated EGFR, leading to tumor recurrence. This evidence concerns the gene EGFR and glioblastoma.